12 yrs knocks off 6 yrs of LL's patent protection,
Post# of 146038
" we do believe that leronlimab could have a significant role in the treatment of MASH, whether as a standalone therapeutic or in a combination therapy approach.”
Why would a new formula, get less than 20 yr?
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)